CLINICAL TRIALS AND OBSERVATIONS

Publication date

September 2016

Abstract

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrom

Extracted data

We use cookies to provide a better user experience.

Data Protection

CLINICAL TRIALS AND OBSERVATIONS

Open link

Publication date

September 2016

Abstract

Extracted data

Selleslag, D.
Suciu, S.
Meloni, G.
Muus, P.
Halkes, C.J.
Venditti, A.
Ramadan, S.M.
Pruijt, H.
Meert, L.
Vignetti, M.
Marie, J.P.
Wittnebel, S.
Witte, T.J. de
Amadori, S.
Willemze, R.
Baron, F.

January 2017

Contains fulltext : 169738.pdf (publisher's version ) (Open Access

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial

Selleslag, Dominik
Suciu, Stefan
Meloni, Giovanna
Muus, Petra
Halkes, Constantijn J. M.
Venditti, Adriano
Ramadan, Safaa M.
Pruijt, Hans
Meert, Liv
Vignetti, Marco
Marie, Jean-Pierre
Wittnebel, Sébastian
de Witte, Theo
Amadori, Sergio
Willemze, Roelof
Baron, Frédéric

January 2017

The prognosis of younger patients with intermediate/high risk acute myelogenous leukemia (AML) or hi...

CLINICAL TRIALS AND OBSERVATIONS Clofarabine

Stefan Faderl
Srdan Verstovsek
Jorge Cortes
Farhad Rav
Miloslav Beran
Guillermo Garcia-manero
Ra Ferrajoli
Zeev Estrov
Charles Koller
Francis J. Giles
William Wierda
Monica Kwari
Hagop M. Kantarjian

October 2016

and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 year...

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Löwenberg, Bob
Pabst, Thomas
Maertens, Johan
van Norden, Yvette
Biemond, Bart J.
Schouten, Harry C.
Spertini, Olivier
Vellenga, Edo
Graux, Carlos
Havelange, Violaine
de Greef, Georgine E
De Weerdt, Okke
Legdeur, Marie-Cecile J C
Kuball, Juergen
van Marwijk Kooy, Marinus
Gjertsen, Bjorn T
Jongen-Lavrencic, Mojca
van de Loosdrecht, Arjan A
van Lammeren-Venema, Daniëlle
Hodossy, Beata
Breems, Dimitri A
Chalandon, Yves
Passweg, Jakob
Valk, Peter J M
Manz, Markus G
Ossenkoppele, Gert J

March 2017

Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be...

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.

Löwenberg, Bob
Pabst, Thomas
Maertens, Johan
van Norden, Yvette
Biemond, Bart J
Schouten, Harry C
Spertini, Olivier
Vellenga, Edo
Graux, Carlos
Havelange, Violaine
de Greef, Georgine E
de Weerdt, Okke
Legdeur, Marie-Cecile J C
Kuball, Juergen
Kooy, Marinus van Marwijk
Gjertsen, Bjorn T
Jongen-Lavrencic, Mojca
van de Loosdrecht, Arjan A
van Lammeren-Venema, Daniëlle
Hodossy, Beata
Breems, Dimitri A
Chalandon, Yves
Passweg, Jakob
Valk, Peter J M
Manz, Markus G
Ossenkoppele, Gert J

March 2017

Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be...

Therapeutic value of clofarabine in younger and middle aged (18 - 65 yrs) adults with newly diagnosed AML.

Löwenberg, Bob
Pabst, Thomas
Maertens, Johan
van Norden, Yvette
Biemond, Bart J
Schouten, Harry C
Spertini, Olivier
Vellenga, Edo
Graux, Carlos
Havelange, Violaine
de Greef, Georgine E
de Weerdt, Okke
Legdeur, Marie-Cecile J C
Kuball, Juergen
van Marwijk Kooy, Marinus
Gjertsen, Bjorn T
Jongen-Lavrencic, Mojca
van de Loosdrecht, Arjan A
van Lammeren-Venema, Daniëlle
Hodossy, Beata
Breems, Dimitri A
Chalandon, Yves
Passweg, Jakob
Valk, Peter J M
Manz, Markus G
Ossenkoppele, Gert J
Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
Swiss Group for Clinical Cancer Research (SAKK)

January 2017

Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be...

European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy

Burnett, Alan Kenneth
Russell, N. H.
Kell, J.
Dennis, M.
Milligan, D.
Paolini, S.
Yin, J.
Culligan, D.
Johnston, P.
Murphy, J.
McMullin, M. F.
Hunter, A.
Das-Gupta, E.
Clark, R.
Carr, R.
Hills, R. K.

January 2010

Purpose Treatment options for older patients with acute myeloid leukemia (AML) who are not considere...

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

Burnett, A K
Russell, N H
Hills, R K
Kell, J
Nielsen, O J
Dennis, M
Cahalin, P
Pocock, C
Ali, S
Burns, S
Freeman, S
Milligan, Donald
Clark, R E

February 2017

The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patie...

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia

Burnett, A
Russell, N
Hills, R
Kell, J
Nielsen, O
Dennis, M
Cahalin, P
Pocock, C
Ali, S
Burns, S
Freeman, S
Milligan, D
Clark, R
behalf of the UK NCRI AML Study Group

January 2016

The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patie...

Selleslag, D.
Suciu, S.
Meloni, G.
Muus, P.
Halkes, C.J.
Venditti, A.
Ramadan, S.M.
Pruijt, H.
Meert, L.
Vignetti, M.
Marie, J.P.
Wittnebel, S.
Witte, T.J. de
Amadori, S.
Willemze, R.
Baron, F.

January 2017

Contains fulltext : 169738.pdf (publisher's version ) (Open Access

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial

Selleslag, Dominik
Suciu, Stefan
Meloni, Giovanna
Muus, Petra
Halkes, Constantijn J. M.
Venditti, Adriano
Ramadan, Safaa M.
Pruijt, Hans
Meert, Liv
Vignetti, Marco
Marie, Jean-Pierre
Wittnebel, Sébastian
de Witte, Theo
Amadori, Sergio
Willemze, Roelof
Baron, Frédéric

January 2017

The prognosis of younger patients with intermediate/high risk acute myelogenous leukemia (AML) or hi...

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Löwenberg, Bob
Pabst, Thomas
Maertens, Johan
van Norden, Yvette
Biemond, Bart J.
Schouten, Harry C.
Spertini, Olivier
Vellenga, Edo
Graux, Carlos
Havelange, Violaine
de Greef, Georgine E
De Weerdt, Okke
Legdeur, Marie-Cecile J C
Kuball, Juergen
van Marwijk Kooy, Marinus
Gjertsen, Bjorn T
Jongen-Lavrencic, Mojca
van de Loosdrecht, Arjan A
van Lammeren-Venema, Daniëlle
Hodossy, Beata
Breems, Dimitri A
Chalandon, Yves
Passweg, Jakob
Valk, Peter J M
Manz, Markus G
Ossenkoppele, Gert J

March 2017

Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be...

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.

Löwenberg, Bob
Pabst, Thomas
Maertens, Johan
van Norden, Yvette
Biemond, Bart J
Schouten, Harry C
Spertini, Olivier
Vellenga, Edo
Graux, Carlos
Havelange, Violaine
de Greef, Georgine E
de Weerdt, Okke
Legdeur, Marie-Cecile J C
Kuball, Juergen
Kooy, Marinus van Marwijk
Gjertsen, Bjorn T
Jongen-Lavrencic, Mojca
van de Loosdrecht, Arjan A
van Lammeren-Venema, Daniëlle
Hodossy, Beata
Breems, Dimitri A
Chalandon, Yves
Passweg, Jakob
Valk, Peter J M
Manz, Markus G
Ossenkoppele, Gert J

March 2017

Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be...

Therapeutic value of clofarabine in younger and middle aged (18 - 65 yrs) adults with newly diagnosed AML.

Löwenberg, Bob
Pabst, Thomas
Maertens, Johan
van Norden, Yvette
Biemond, Bart J
Schouten, Harry C
Spertini, Olivier
Vellenga, Edo
Graux, Carlos
Havelange, Violaine
de Greef, Georgine E
de Weerdt, Okke
Legdeur, Marie-Cecile J C
Kuball, Juergen
van Marwijk Kooy, Marinus
Gjertsen, Bjorn T
Jongen-Lavrencic, Mojca
van de Loosdrecht, Arjan A
van Lammeren-Venema, Daniëlle
Hodossy, Beata
Breems, Dimitri A
Chalandon, Yves
Passweg, Jakob
Valk, Peter J M
Manz, Markus G
Ossenkoppele, Gert J
Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
Swiss Group for Clinical Cancer Research (SAKK)

January 2017

Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be...

European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy

Burnett, Alan Kenneth
Russell, N. H.
Kell, J.
Dennis, M.
Milligan, D.
Paolini, S.
Yin, J.
Culligan, D.
Johnston, P.
Murphy, J.
McMullin, M. F.
Hunter, A.
Das-Gupta, E.
Clark, R.
Carr, R.
Hills, R. K.

January 2010

Purpose Treatment options for older patients with acute myeloid leukemia (AML) who are not considere...

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

Burnett, A K
Russell, N H
Hills, R K
Kell, J
Nielsen, O J
Dennis, M
Cahalin, P
Pocock, C
Ali, S
Burns, S
Freeman, S
Milligan, Donald
Clark, R E

February 2017

The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patie...

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia

Burnett, A
Russell, N
Hills, R
Kell, J
Nielsen, O
Dennis, M
Cahalin, P
Pocock, C
Ali, S
Burns, S
Freeman, S
Milligan, D
Clark, R
behalf of the UK NCRI AML Study Group

January 2016

The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patie...

Selleslag, D.
Suciu, S.
Meloni, G.
Muus, P.
Halkes, C.J.
Venditti, A.
Ramadan, S.M.
Pruijt, H.
Meert, L.
Vignetti, M.
Marie, J.P.
Wittnebel, S.
Witte, T.J. de
Amadori, S.
Willemze, R.
Baron, F.

January 2017

Contains fulltext : 169738.pdf (publisher's version ) (Open Access

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial

Selleslag, Dominik
Suciu, Stefan
Meloni, Giovanna
Muus, Petra
Halkes, Constantijn J. M.
Venditti, Adriano
Ramadan, Safaa M.
Pruijt, Hans
Meert, Liv
Vignetti, Marco
Marie, Jean-Pierre
Wittnebel, Sébastian
de Witte, Theo
Amadori, Sergio
Willemze, Roelof
Baron, Frédéric

January 2017

The prognosis of younger patients with intermediate/high risk acute myelogenous leukemia (AML) or hi...

Related items

Selleslag, D.
Suciu, S.
Meloni, G.
Muus, P.
Halkes, C.J.
Venditti, A.
Ramadan, S.M.
Pruijt, H.
Meert, L.
Vignetti, M.
Marie, J.P.
Wittnebel, S.
Witte, T.J. de
Amadori, S.
Willemze, R.
Baron, F.

January 2017

Contains fulltext : 169738.pdf (publisher's version ) (Open Access

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial

Selleslag, Dominik
Suciu, Stefan
Meloni, Giovanna
Muus, Petra
Halkes, Constantijn J. M.
Venditti, Adriano
Ramadan, Safaa M.
Pruijt, Hans
Meert, Liv
Vignetti, Marco
Marie, Jean-Pierre
Wittnebel, Sébastian
de Witte, Theo
Amadori, Sergio
Willemze, Roelof
Baron, Frédéric

January 2017

The prognosis of younger patients with intermediate/high risk acute myelogenous leukemia (AML) or hi...

CLINICAL TRIALS AND OBSERVATIONS Clofarabine

Stefan Faderl
Srdan Verstovsek
Jorge Cortes
Farhad Rav
Miloslav Beran
Guillermo Garcia-manero
Ra Ferrajoli
Zeev Estrov
Charles Koller
Francis J. Giles
William Wierda
Monica Kwari
Hagop M. Kantarjian

October 2016

and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 year...

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Löwenberg, Bob
Pabst, Thomas
Maertens, Johan
van Norden, Yvette
Biemond, Bart J.
Schouten, Harry C.
Spertini, Olivier
Vellenga, Edo
Graux, Carlos
Havelange, Violaine
de Greef, Georgine E
De Weerdt, Okke
Legdeur, Marie-Cecile J C
Kuball, Juergen
van Marwijk Kooy, Marinus
Gjertsen, Bjorn T
Jongen-Lavrencic, Mojca
van de Loosdrecht, Arjan A
van Lammeren-Venema, Daniëlle
Hodossy, Beata
Breems, Dimitri A
Chalandon, Yves
Passweg, Jakob
Valk, Peter J M
Manz, Markus G
Ossenkoppele, Gert J

March 2017

Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be...

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.

Löwenberg, Bob
Pabst, Thomas
Maertens, Johan
van Norden, Yvette
Biemond, Bart J
Schouten, Harry C
Spertini, Olivier
Vellenga, Edo
Graux, Carlos
Havelange, Violaine
de Greef, Georgine E
de Weerdt, Okke
Legdeur, Marie-Cecile J C
Kuball, Juergen
Kooy, Marinus van Marwijk
Gjertsen, Bjorn T
Jongen-Lavrencic, Mojca
van de Loosdrecht, Arjan A
van Lammeren-Venema, Daniëlle
Hodossy, Beata
Breems, Dimitri A
Chalandon, Yves
Passweg, Jakob
Valk, Peter J M
Manz, Markus G
Ossenkoppele, Gert J

March 2017

Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be...

Therapeutic value of clofarabine in younger and middle aged (18 - 65 yrs) adults with newly diagnosed AML.

Löwenberg, Bob
Pabst, Thomas
Maertens, Johan
van Norden, Yvette
Biemond, Bart J
Schouten, Harry C
Spertini, Olivier
Vellenga, Edo
Graux, Carlos
Havelange, Violaine
de Greef, Georgine E
de Weerdt, Okke
Legdeur, Marie-Cecile J C
Kuball, Juergen
van Marwijk Kooy, Marinus
Gjertsen, Bjorn T
Jongen-Lavrencic, Mojca
van de Loosdrecht, Arjan A
van Lammeren-Venema, Daniëlle
Hodossy, Beata
Breems, Dimitri A
Chalandon, Yves
Passweg, Jakob
Valk, Peter J M
Manz, Markus G
Ossenkoppele, Gert J
Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
Swiss Group for Clinical Cancer Research (SAKK)

January 2017

Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be...

European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy

Burnett, Alan Kenneth
Russell, N. H.
Kell, J.
Dennis, M.
Milligan, D.
Paolini, S.
Yin, J.
Culligan, D.
Johnston, P.
Murphy, J.
McMullin, M. F.
Hunter, A.
Das-Gupta, E.
Clark, R.
Carr, R.
Hills, R. K.

January 2010

Purpose Treatment options for older patients with acute myeloid leukemia (AML) who are not considere...

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

Burnett, A K
Russell, N H
Hills, R K
Kell, J
Nielsen, O J
Dennis, M
Cahalin, P
Pocock, C
Ali, S
Burns, S
Freeman, S
Milligan, Donald
Clark, R E

February 2017

The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patie...

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia

Burnett, A
Russell, N
Hills, R
Kell, J
Nielsen, O
Dennis, M
Cahalin, P
Pocock, C
Ali, S
Burns, S
Freeman, S
Milligan, D
Clark, R
behalf of the UK NCRI AML Study Group

January 2016

The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patie...

Selleslag, D.
Suciu, S.
Meloni, G.
Muus, P.
Halkes, C.J.
Venditti, A.
Ramadan, S.M.
Pruijt, H.
Meert, L.
Vignetti, M.
Marie, J.P.
Wittnebel, S.
Witte, T.J. de
Amadori, S.
Willemze, R.
Baron, F.

January 2017

Contains fulltext : 169738.pdf (publisher's version ) (Open Access

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial

Selleslag, Dominik
Suciu, Stefan
Meloni, Giovanna
Muus, Petra
Halkes, Constantijn J. M.
Venditti, Adriano
Ramadan, Safaa M.
Pruijt, Hans
Meert, Liv
Vignetti, Marco
Marie, Jean-Pierre
Wittnebel, Sébastian
de Witte, Theo
Amadori, Sergio
Willemze, Roelof
Baron, Frédéric

January 2017

The prognosis of younger patients with intermediate/high risk acute myelogenous leukemia (AML) or hi...

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Löwenberg, Bob
Pabst, Thomas
Maertens, Johan
van Norden, Yvette
Biemond, Bart J.
Schouten, Harry C.
Spertini, Olivier
Vellenga, Edo
Graux, Carlos
Havelange, Violaine
de Greef, Georgine E
De Weerdt, Okke
Legdeur, Marie-Cecile J C
Kuball, Juergen
van Marwijk Kooy, Marinus
Gjertsen, Bjorn T
Jongen-Lavrencic, Mojca
van de Loosdrecht, Arjan A
van Lammeren-Venema, Daniëlle
Hodossy, Beata
Breems, Dimitri A
Chalandon, Yves
Passweg, Jakob
Valk, Peter J M
Manz, Markus G
Ossenkoppele, Gert J

March 2017

Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be...

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.

Löwenberg, Bob
Pabst, Thomas
Maertens, Johan
van Norden, Yvette
Biemond, Bart J
Schouten, Harry C
Spertini, Olivier
Vellenga, Edo
Graux, Carlos
Havelange, Violaine
de Greef, Georgine E
de Weerdt, Okke
Legdeur, Marie-Cecile J C
Kuball, Juergen
Kooy, Marinus van Marwijk
Gjertsen, Bjorn T
Jongen-Lavrencic, Mojca
van de Loosdrecht, Arjan A
van Lammeren-Venema, Daniëlle
Hodossy, Beata
Breems, Dimitri A
Chalandon, Yves
Passweg, Jakob
Valk, Peter J M
Manz, Markus G
Ossenkoppele, Gert J

March 2017

Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be...

Therapeutic value of clofarabine in younger and middle aged (18 - 65 yrs) adults with newly diagnosed AML.

Löwenberg, Bob
Pabst, Thomas
Maertens, Johan
van Norden, Yvette
Biemond, Bart J
Schouten, Harry C
Spertini, Olivier
Vellenga, Edo
Graux, Carlos
Havelange, Violaine
de Greef, Georgine E
de Weerdt, Okke
Legdeur, Marie-Cecile J C
Kuball, Juergen
van Marwijk Kooy, Marinus
Gjertsen, Bjorn T
Jongen-Lavrencic, Mojca
van de Loosdrecht, Arjan A
van Lammeren-Venema, Daniëlle
Hodossy, Beata
Breems, Dimitri A
Chalandon, Yves
Passweg, Jakob
Valk, Peter J M
Manz, Markus G
Ossenkoppele, Gert J
Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
Swiss Group for Clinical Cancer Research (SAKK)

January 2017

Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be...

European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy

Burnett, Alan Kenneth
Russell, N. H.
Kell, J.
Dennis, M.
Milligan, D.
Paolini, S.
Yin, J.
Culligan, D.
Johnston, P.
Murphy, J.
McMullin, M. F.
Hunter, A.
Das-Gupta, E.
Clark, R.
Carr, R.
Hills, R. K.

January 2010

Purpose Treatment options for older patients with acute myeloid leukemia (AML) who are not considere...

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

Burnett, A K
Russell, N H
Hills, R K
Kell, J
Nielsen, O J
Dennis, M
Cahalin, P
Pocock, C
Ali, S
Burns, S
Freeman, S
Milligan, Donald
Clark, R E

February 2017

The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patie...

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia

Burnett, A
Russell, N
Hills, R
Kell, J
Nielsen, O
Dennis, M
Cahalin, P
Pocock, C
Ali, S
Burns, S
Freeman, S
Milligan, D
Clark, R
behalf of the UK NCRI AML Study Group

January 2016

The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patie...

Selleslag, D.
Suciu, S.
Meloni, G.
Muus, P.
Halkes, C.J.
Venditti, A.
Ramadan, S.M.
Pruijt, H.
Meert, L.
Vignetti, M.
Marie, J.P.
Wittnebel, S.
Witte, T.J. de
Amadori, S.
Willemze, R.
Baron, F.

January 2017

Contains fulltext : 169738.pdf (publisher's version ) (Open Access

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial

Selleslag, Dominik
Suciu, Stefan
Meloni, Giovanna
Muus, Petra
Halkes, Constantijn J. M.
Venditti, Adriano
Ramadan, Safaa M.
Pruijt, Hans
Meert, Liv
Vignetti, Marco
Marie, Jean-Pierre
Wittnebel, Sébastian
de Witte, Theo
Amadori, Sergio
Willemze, Roelof
Baron, Frédéric

January 2017

The prognosis of younger patients with intermediate/high risk acute myelogenous leukemia (AML) or hi...